FDA clears 1st blood test for Alzheimer’s in primary care / Beckers

Ella Jeffries / beckershospitalreview - The first FDA-cleared blood test to assess Alzheimer’s disease in primary care is now available for patients age 55 and older with symptoms of cognitive decline. The test aims to help clinicians rule out Alzheimer’s by identifying individuals unlikely to …

#healthcare #publichealth #governmentpolicy #biotech #fda

A possible Alzheimer's biomarker? Why REST protein levels are drawing attention

25 days / medicalxpress

J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug

25 days / endpoints / Elizabeth Cairns

Blood test 'clocks' can predict when Alzheimer's symptoms will start

25 days / medicalxpress

Viagra and shingles vaccine show surprising promise against Alzheimer’s

26 days / sciencedaily

Paragon's new biotech Korsana tackles Alzheimer's like Roche

26 days / endpoints / Kyle LaHucik

Air pollution may directly contribute to Alzheimer's disease

27 days / medicalxpress

The good side of a side effect: Brain swelling during Alzheimer's treatment may signal strong response

27 days / medicalxpress

Connecting the dots between cause-effect events in Alzheimer's disease

28 days / medicalxpress

Alzheimer's gene boosts seizures, but pathway can be targeted, study finds

28 days / medicalxpress

Senescent astrocytes discovered in Alzheimer's brains point to new treatment targets

28 days / medicalxpress

Hearing loss and cognitive decline in presbycusis may be linked via neural activity fluctuations, cell death

28 days / medicalxpress

Neurodegenerative diseases need more mechanism-informed trials

29 days / nature

A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders

29 days / nature / Katharina Bolsewig

Your morning coffee might protect your brain as you age. Here's the sweet spot

29 days / medicalxpress

Menopause, hormones and the brain: How hormone therapy could help protect against Alzheimer's

4 wks / medicalxpress

Blood-based tests show strong promise for dementia diagnosis—but population diversity matters

4 wks / medicalxpress

FDA clears 1st blood test for Alzheimer’s in primary care

4 wks / beckershospitalreview / Ella Jeffries

Capillary blood sampling for detecting biomarkers of Alzheimer’s disease

4 wks / nature

Saturday, February 14, 2026, 4:21 am / permalink 19180 / 18 stories in 4 wks



Related Stories



Related Tags


Healthcare

EPA proposes rollback on ethylene oxide sterilizer emissions (11 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (18 hrs)

more #healthcare


Public Health

EPA proposes rollback on ethylene oxide sterilizer emissions (11 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (21 hrs)

more #publichealth


Government Policy

EPA proposes rollback on ethylene oxide sterilizer emissions (11 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

FDA approves leucovorin for rare folate disorder despite autism hype (34 hrs)

more #governmentpolicy


StackHealth Time Machine



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.